Validation of analytic methods for biomarkers used in drug development
about
Proteomics and metabolomics in renal transplantation-quo vadis?Vitamin D as Adjunctive Host-Directed Therapy in Tuberculosis: A Systematic ReviewValidation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validationRecommendations for Use and Fit-for-Purpose Validation of Biomarker Multiplex Ligand Binding Assays in Drug Development.Evaluation of optical detection platforms for multiplexed detection of proteins and the need for point-of-care biosensors for clinical useUrinary biomarkers of smokers' exposure to tobacco smoke constituents in tobacco products assessment: a fit for purpose approachBiomarkers of Tobacco Exposure: Summary of an FDA-sponsored Public WorkshopProteomics and biomarkers in clinical trials for drug developmentFormulation and Development of a Validated UV-Spectrophotometric Analytical Method of Rutin Tablet.Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology.Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors.Aqueous two-phase systems enable multiplexing of homogeneous immunoassays.Designing biomarker studies for head and neck cancer.Prognostic biomarkers in ovarian cancer.Application of quantitative pharmacology in development of therapeutic monoclonal antibodiesValidity of clinical associations of biomarkers in translational research studies: the case of systemic autoimmune diseasesPredictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation.MicroRNA signatures as biomarkers and therapeutic target for CNS embryonal tumors: the pros and the cons.Comparison of quantitative parameters in cervix cancer measured by dynamic contrast-enhanced MRI and CT.Elevated Muscle-Specific miRNAs in Serum of Myotonic Dystrophy Patients Relate to Muscle Disease Progress.Optimisation of immunofluorescence methods to determine MCT1 and MCT4 expression in circulating tumour cellsMolecular classifiers for acute kidney transplant rejection in peripheral blood by whole genome gene expression profiling.When close is not close enough: a comparison of endogenous and recombinant biomarker stability samples.Development and use of integral assays in clinical trialsBridging the gap: moving predictive and prognostic assays from research to clinical useImpact of preanalytic factors on the design and application of integral biomarkers for directing patient therapySerum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers.Implementation of proteomic biomarkers: making it work.A meta-analysis of CXCL12 expression for cancer prognosis.Issues and applications in label-free quantitative mass spectrometry.Development of a standardized flow cytometric method to conduct longitudinal analyses of intracellular CD3ζ expression in patients with head and neck cancer.Validation of commercially available ELISAs for the detection of circulating sclerostin in hemodialysis patientsGenomic biomarkers for personalized medicine: development and validation in clinical studiesLung cancer biomarkers for the assessment of modified risk tobacco products: an oxidative stress perspectivePersonalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer.Monitor tumor burden with circulating tumor DNA.Unblocking blockbusters: using boolean text-mining to optimise clinical trial design and timeline for novel anticancer drugs.Recommendations and best practices for reference standards and reagents used in bioanalytical method validation.DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.
P2860
Q27024418-85A309F9-5AB1-4BB7-A53D-9D2E0C56AB47Q28071387-D5E92E4C-E3EC-414D-AFA7-CD49456C9814Q28075719-EAFD3B15-D4F9-433E-B451-1324E1E5BBCEQ28081875-3A554616-AD50-4170-9712-7372E09410C4Q28652076-A8B1C236-BE24-488D-96CD-52381B4257F9Q28662000-FEC77FDD-F943-47E9-A13A-842DD0740A3CQ29248704-298F9505-3E09-45FC-9F7A-800B46C3055AQ30402667-9D621129-2E66-4C2F-B4FE-1CF59842CC48Q33737806-3E14A0F9-73B3-4884-8B69-C4748F1F80F0Q33775506-69355549-2094-4BF1-B913-C2CA4247BF1AQ33846801-61BF460B-37D7-40DA-B105-0AE12EA4E8FBQ33935045-653E96E0-D43E-48E5-B8E9-2E071A401BA8Q33965654-BB347E10-5AE5-4861-9702-E7CD728CF6FAQ33971467-C22E8B9C-48B9-444D-A198-BC53E8D950FEQ34086636-23D33892-BF1D-416E-82C4-1B245E6E9976Q34293689-CB8ACD56-63E8-4994-86EE-3366A1F9F590Q34346280-94F9C46A-C0D7-4497-AF86-5057376640A2Q34620545-2D36181F-FAFD-4C3A-BBD2-60B3B435381CQ34685896-F074B11D-006C-4F57-816A-86B2CAB717E1Q34952709-33D8E056-184F-4BDE-A4AB-887E105F0EBDQ35542688-1BD01533-298F-4642-83AD-3135A884C838Q35626055-AA98BE57-5080-4B20-8BCC-C167D5874DA4Q35629098-DA6B5679-580F-4275-AE97-D0172087CD77Q35674203-CB4C9624-FA9B-43E9-86B4-A8CB3C01EAF5Q35838558-AAC2EF37-82CF-4986-AF39-913E9BE33E77Q35838577-9F8415EB-D20D-48A0-832E-EECBA4CC73C3Q35840045-0BFACCD5-BDE5-4BA0-8805-48B6C975651EQ35885064-8DB7EFE5-04B2-4178-B07F-E7568D6599FDQ36297774-786C6164-93ED-4FE0-912C-46D933423DEFQ36378583-612F9D0E-BC31-414A-988A-DA4562FF90A4Q36582749-7529170C-2136-45AE-B1D1-A9348BE456C4Q36640727-15CEE4AE-DFB3-4A3E-A4B4-69A281402717Q36793394-0C923532-3509-49BD-930E-C5C2B199D1B9Q36837848-F9719349-A8AA-4387-A107-AC6C6C607981Q36887208-F1AC1024-8769-4FF6-B320-DBE5EBCF675CQ36964450-C4FFFFC2-5232-45C2-9811-DD05840DAEEFQ37344457-441BB5BD-0B51-4B7E-A957-EDDC043E496FQ37469238-153E3235-A66D-4CB2-B5D4-4FED34907158Q37601046-A92DBA76-BA04-4AAF-B3AE-F630761BC450Q37619866-A19F5C5E-A0AF-4FC8-827F-AEF41140756C
P2860
Validation of analytic methods for biomarkers used in drug development
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Validation of analytic methods for biomarkers used in drug development
@en
Validation of analytic methods for biomarkers used in drug development.
@nl
type
label
Validation of analytic methods for biomarkers used in drug development
@en
Validation of analytic methods for biomarkers used in drug development.
@nl
prefLabel
Validation of analytic methods for biomarkers used in drug development
@en
Validation of analytic methods for biomarkers used in drug development.
@nl
P2093
P2860
P1476
Validation of analytic methods for biomarkers used in drug development
@en
P2093
Cindy H Chau
Howard McLeod
William D Figg
P2860
P304
P356
10.1158/1078-0432.CCR-07-4535
P407
P50
P577
2008-10-01T00:00:00Z